Research article summary (published 30 Oct 2009):

Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells.

Full Abstract

We have analyzed the gene modulation induced by zoledronic acid (ZOL) in androgen-resistant prostate cancer PC3 cells with cDNA microarray platform to identify new molecular targets of ZOL in prostate cancer. The gene coding for cysteine-rich, angiogenic inducer, 61 (CYR61) resulted highly downregulated with a fold change of 5.58. Therefore, we have studied the effects of ZOL on CYR61 protein product, and we have found that CYR61 protein expression was decreased significantly after exposure to ZOL. The effect of ZOL on CYR61 expression was dose and time dependent was due to a reduced transcriptional activity of CYR61 promoter. Moreover, the effects induced by ZOL were paralleled by decreased activation of Ras-Raf-1- and Akt-dependent pathways that was dependent from isoprenylation inhibition, since it was antagonized by the addition of geranylgeraniol. Finally, we have investigated the role of CYR61 in the regulation of growth inhibition and invasion/motility of PC3 cells using a shRNA for CYR61 to downregulate the expression of CYR61 protein. The enhanced inhibition of proliferation and motility/invasion induced by ZOL by S-phase accumulation. In the same experimental conditions, CYR61 protein downregulation potentiated the inactivation of the Ras-dependent proliferation pathway and cell cycle inhibitors p21 and p27 expression. (c) 2009 UICC.

Author information

Author/s: Marra, Monica (M); Santini, Daniele (D); Meo, Giuseppina (G); Vincenzi, Bruno (B); Zappavigna, Silvia (S); Baldi, Alfonso (A); Rosolowski, Maciej (M); Tonini, Giuseppe (G); Loeffler, Markus (M); Lupu, Ruth (R); Addeo, Santolo Rosario (SR); Abbruzzese, Alberto (A); Budillon, Alfredo (A); Caraglia, Michele (M);

Affiliation: Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy.

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal: International journal of cancer. Journal international du cancer (Int J Cancer), published in United States. (Language: eng)

Reference: 2009-Nov; vol 125 (issue 9) : pp 2004-13

Dates: Created 2009/09/03; Completed 2009/09/15;

PMID: 19530242, status: MEDLINE (last retrieval date: 9/15/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Antineoplastic Agents - pharmacology Cell Cycle - drug effects Cell Line, Tumor Cell Proliferation - drug effects Cysteine-Rich Protein 61 - analysis; antagonists & inhibitors; genetics Diphosphonates - pharmacology Humans Imidazoles - pharmacology

Imidazoles - pharmacology Male Neoplasm Invasiveness Oligonucleotide Array Sequence Analysis Promoter Regions, Genetic Prostatic Neoplasms - drug therapy; pathology Protein Prenylation Signal Transduction - drug effects

Associated Chemicals: Antineoplastic Agents (0) ; CYR61 protein, human (0) ; Cysteine-Rich Protein 61 (0) ; Diphosphonates (0) ; Imidazoles (0) ; zoledronic acid (118072-93-8)

Related articles

These are the highest related articles currently in the database:

• Bisphosphonate treatment inhibits the growth of prostate cancer cells. 13 Mar 2001
• Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. 30 Oct 2005
• R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. 29 Apr 2007
• Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. 30 May 2006
• Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. 10 Jan 2007
• Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. 25 Dec 2007
• The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. 30 Dec 2006
• Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. 30 Dec 2004
• Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. 30 Dec 2004
• Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. 13 Mar 2006

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.